Compare PRMB & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRMB | BLCO |
|---|---|---|
| Founded | 1955 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Ophthalmic Goods |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | PRMB | BLCO |
|---|---|---|
| Price | $21.41 | $17.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $28.80 | $18.55 |
| AVG Volume (30 Days) | ★ 5.3M | 454.5K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $2.31 | $8.61 |
| Revenue Next Year | $3.55 | $5.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $14.36 | $10.45 |
| 52 Week High | $35.85 | $18.92 |
| Indicator | PRMB | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 46.03 |
| Support Level | $15.21 | $16.35 |
| Resistance Level | $22.96 | $17.66 |
| Average True Range (ATR) | 0.78 | 0.52 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 63.06 | 23.28 |
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.